GlaxoSmithKline To Pay $75M To Settle Patent Suit

Law360, New York (May 25, 2004, 12:00 AM EDT) -- GlaxoSmithKline has agreed to pay $75 million dollars to settle a drug patent lawsuit brought by a consumer group that had accused the U.K. drug maker of using illegal tactics to maintain its patent on the anti-inflammatory drug Relafen and keep a cheaper generic version off the market.

The settlement, which must be approved by the U.S. District Court Judge William G. Young in Boston, is over a lawsuit brought last year by the consumer group Prescription Access Litigation.

PAL, a nationwide coalition of 93 consumer...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.